Cargando…

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria, Matthews, David R.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Emerging Treatments and Technologies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/ https://www.ncbi.nlm.nih.gov/pubmed/18931095 http://dx.doi.org/10.2337/dc08-1355

Ejemplares similares

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Racial/Ethnic Differences in Concerns About Current and Future Medications Among Patients With Type 2 Diabetes
por: Huang, Elbert S., et al.
Publicado: (2009)

Liraglutide Overdose-Induced Acute Pancreatitis
por: AlSaadoun, Aljawhara R, et al.
Publicado: (2022)

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients : Effects of monotherapy with rimonabant, the first selective CB(1) receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2008)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study
por: Nyström, Thomas, et al.
Publicado: (2019)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Novel Noninvasive Breath Test Method for Screening Individuals at Risk for Diabetes
por: Dillon, E. Lichar, et al.
Publicado: (2009)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2017)

Feasibility of 10-Day Use of a Continuous Glucose-Monitoring System in Adults With Type 1 Diabetes
por: Garg, Satish K., et al.
Publicado: (2009)

Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome
por: Livadas, S, et al.
Publicado: (2020)

Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
por: Cherney, David Z.I., et al.
Publicado: (2009)

Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2018)

Non-diabetic use of liraglutide
por: Verma, Abhyudaya
Publicado: (2012)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
por: Zinman, Bernard, et al.
Publicado: (2009)

A New Luminescence Assay for Autoantibodies to Mammalian Cell–Prepared Insulinoma-Associated Protein 2
por: Burbelo, Peter D., et al.
Publicado: (2008)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato, Mauro, et al.
Publicado: (2014)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
por: Liu, Ying, et al.
Publicado: (2017)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
por: Sjöholm, Åke
Publicado: (2010)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021)

The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
por: Zhao, Na, et al.
Publicado: (2021)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects
por: Wang, Zhang, et al.
Publicado: (2017)

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
por: Russell-Jones, D., et al.
Publicado: (2009)

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
por: Smith, Steve R., et al.
Publicado: (2008)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
por: Ito, Daisuke, et al.
Publicado: (2015)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
por: Zameer, Rafia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8snioj1vg1866pbt0gk2rmaphd